Australia markets closed

Radiopharm Theranostics Limited (RAD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.03000.0000 (0.00%)
At close: 03:51PM AEST

Radiopharm Theranostics Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
61 3 9824 5254

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder & Executive Chairman271.45kN/A1956
Mr. Riccardo CanevariMD, CEO & Director1.51MN/AN/A
Mr. Vittorio Puppo M.D.Chief Operating Officer1.03MN/AN/A
Prof. David MozleyChief Medical Officer & Scientific Advisory Board Chair765.76kN/AN/A
Dr. Thomas H. Tulip Ph.D.Chief Business Officer504.74kN/A1953
Mr. Phillip HainsCFO, Company Secretary & DirectorN/AN/AN/A
Dr. Scot L. Harper Ph.D.Senior Vice President of Clinical OperationsN/AN/A1957
Mr. Bill ReganSenior Vice President of Regulatory StrategyN/AN/AN/A
Dr. Rama Abu ShmeisSenior VP of Chemistry, Manufacturing & ControlsN/AN/AN/A
Mr. Nathan Jong C.A.Company SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.

Corporate governance

Radiopharm Theranostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.